GTHR GeneThera Inc (CE)

GeneThera, Inc. (PINKSHEETS: GTHR) announced today it is offering discounted Johne's disease tests to all dairymen. For the next six months, GeneThera will offer their Real Time PCR test directly to dairymen at the reduced price of only $14.95. The move comes in the wake of recent governmental requests for the reduction of at least 400,000 dairy cattle. The requested reduction in the overall herd size is due to the glut of milk on the market and the continually dropping price the farmers are paid for their milk.

According to an October 2000 article in the Wisconsin State Journal, 10% of dairy cows are infected with Johne's disease. U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) has published results which indicate herds infected with Johne's disease cost dairymen $227 per head per year.

"In simple terms, if the dairymen clean their herds completely of Mycobacterium Paratuberculosis, the bacteria that causes Johne's disease, they ultimately should produce more milk with fewer animals. By removing infected cows from the dairy industry, individual farmers should see an increase in production and margins," stated GeneThera CEO, Dr. Antonio Milici, MD, PHD.

According to The Times-News, Twin Falls, Idaho, "Dairymen will send a shockwave through the cattle industry within the year, as milk producers begin the removal of an estimated 400,000 cows from dairy herds across the United States. The dairy industry wants to thin herds in order to cut milk production and boost raw milk prices, which have been declining. Thinning herds and the likely closure of some small dairies could have broad economic repercussions for Idaho, the nation's third-largest milk producer with about 556,000 dairy cows, and the Magic Valley, which produces about half of the state's dairy products."

The states most affected by this reduction in dairy cows are Wisconsin, California, New York, Pennsylvania, Minnesota and Idaho.

"Our concern here is both for the dairy industry as a whole, and the American people. It has been proven that Mycobacterium Paratuberculosis is not completely eliminated during the pasteurization process, and live cultures survive in the products we eat and drink every day. The only way to be sure we are not ingesting these bacteria is to eliminate them at the source. Currently a link is being made between Mycobacterium Paratuberculosis, Crohn's disease, and/or IBS. We want to do our part in protecting the general public. We also want to assist the dairy industry in any way we can to help them through these difficult times."

The company states that its Real Time PCR test is much more accurate and timely than what is commonly available today.

Dairymen and dairy industry representatives are urged to contact GeneThera for complete details on how to obtain their discounted Johne's disease tests. Interested dairymen may contact GeneThera by calling (303) 463-6371.

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony Milici, MD, PHD at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370. Dr. Tony Milici was recently nominated to the National Advisory Committee on Meat & Poultry.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

Contact: Dr. Tony Milici 303-463-6371 Goldsmith Group 303-838-4370 JR Dopkin & Associates 516-884-3200